MSI Financial Services’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
$112K Sell
1,528
-15
-1% -$1.22K ﹤0.01% 1396
2016
Q3
$135K Sell
1,543
-86
-5% -$8.13K ﹤0.01% 1263
2016
Q2
$141K Sell
1,629
-159
-9% -$13.7K 0.01% 1214
2016
Q1
$142K Sell
1,788
-277
-13% -$25.1K 0.01% 1162
2015
Q4
$260K Buy
2,065
+957
+86% +$116K 0.01% 816
2015
Q3
$115K Sell
1,108
-6,417
-85% -$824K 0.01% 858
2015
Q2
$929K Buy
7,525
+6,335
+532% +$798K 0.07% 310
2015
Q1
$140K Buy
1,190
+1,128
+1,819% +$135K 0.01% 866
2014
Q4
$7K Buy
62
+5
+9% +$563 ﹤0.01% 2022
2014
Q3
$6K Buy
57
+1
+2% +$95 ﹤0.01% 2057
2014
Q2
$5K Sell
56
-39
-41% -$2.73K ﹤0.01% 2096
2014
Q1
$7K Sell
95
-3
-3% -$238 ﹤0.01% 1890
2013
Q4
$7K Buy
98
+63
+180% +$4.39K ﹤0.01% 1853
2013
Q3
$3K Sell
35
-100
-74% -$7.96K ﹤0.01% 1882
2013
Q2
$11K Buy
+135
New +$9.94K ﹤0.01% 1516

Other funds holding VRTX

MSI Financial Services's VRTX Position: Q4 2016 in Review

MSI Financial Services reduced its Vertex Pharmaceuticals (VRTX) stake by 0.97% in Q4 2016, selling an estimated $1.22K and leaving 1,528 shares worth $112K. The position accounts for ﹤0.01% of the portfolio, ranked #1396.

MSI Financial Services first reported a position in VRTX in Q2 2013 and has held it in 15 quarters since. The position peaked at $929K in Q2 2015. 483 funds tracked by Wall St. Rank hold VRTX as of Q4 2016.

  • MSI Financial Services held 1,528 shares of Vertex Pharmaceuticals worth $112K as of Q4 2016.
  • MSI Financial Services sold 15 Vertex Pharmaceuticals shares in Q4 2016, an estimated $1.22K.
  • Vertex Pharmaceuticals made up ﹤0.01% of MSI Financial Services's portfolio in Q4 2016, its #1396 holding.
  • MSI Financial Services first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • MSI Financial Services's Vertex Pharmaceuticals position peaked at $929K in Q2 2015.
  • 483 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2016.

Based on MSI Financial Services's 13F filing for Q4 2016, filed 13 Jan 2017.